Arbor Biotechnologies
Cambridge, US · Founded 2016 · Delaware corporation · 5 known investors
Arbor develops programmable DNA editors for genetic medicine, aiming to enable functional cures for patients by addressing genetic diseases through bespoke gene editing approaches. The company is developing a portfolio of DNA editing technologies capable of targeting over 90% of the human genome for therapeutic applications.
Founders & leadership
KC
KEITH CRANDELLDirector
DA
DAVID ARTHUR SCOTTExecutive Officer
WX
WINSTON XIA YANExecutive Officer
AH
ANNIE HAZLEHURSTDirector
FZ
FENG ZHANGDirector
DR
DAVID R. WALTDirector
Investors · 5
Reported raises · per SEC filings
Form D private placements▶$215MraisedNov 2021 · 37 investors · BiotechnologyRule 506(b)
▶$215MraisedNov 2021 · 37 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- DAVID CHENGExecutive Officer
- PAUL MEISTERDirector
- RAMI HARAWIDirector
- KEITH CRANDELLDirector
- KELLY MORGANExecutive Officer
- JOHN MURPHYExecutive Officer
- MARK ANGELINODirector
- PAM STETKIEWICZExecutive Officer
- DEVYN SMITHExecutive Officer, Director
- CHEN YUDirector
- DAVID WALTDirector
- Offering amount
- $215M
- Amount sold
- $215M
- First sale
- Oct 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$15.6MraisedAug 2017 · 10 investors · BiotechnologyRule 506(b)
▶$15.6MraisedAug 2017 · 10 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- KEITH CRANDELLDirector
- DAVID R. WALTDirector
- DAVID ARTHUR SCOTTExecutive Officer
- WINSTON XIA YANExecutive Officer
- ANNIE HAZLEHURSTDirector
- FENG ZHANGDirector
- Offering amount
- $15.6M
- Amount sold
- $15.6M
- First sale
- May 2017
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.